ABSTRACT
The Indian poultry market is estimated to have an annual growth rate of 8.1% as of today. However, infectious diseases in poultry pose an important constraint in the growth and development of this sector in our region. Among infectious diseases, viral diseases of poultry pose a serious threat to the poultry industry from an economic point of view. Several viral disease outbreaks have been reported by various researchers from different parts of the country. Among the common viral diseases of poultry, incidences of Newcastle disease, Avian Influenza, Fowl Pox, Infectious Bursal Disease, Marek's disease, Infectious Bronchitis, Infectious Laryngotracheitis and Inclusion Body Hepatitis are significant in Assam as well as other parts of India. Thorough epidemiological studies followed by the identification of different serotypes, pathotypes, strains, etc. by genotyping and molecular characterization of viral disease pathogens may lead to ways to control and eradicate the diseases. Importance should be given to maintaining basic preventive measures like biosecurity, farm hygiene, and proper vaccination. In a developing country like India, disease outbreaks can impact the country's economy. In this study, a brief view of the common viral disease of poultry and its diagnosis and control strategies in Assam, India is depicted. However, this review well indicates a plethora of avian diseases that have occurred over the years causing a severe impact on poultry farming as a whole.
ABSTRACT
Practically the entire global population is infected by herpesviruses that establish lifelong latency and can be reactivated. Alpha-herpesviruses, herpes simplex viruses 1 and 2 (HSV-1/HSV-2) and varicella zoster virus (VZV), establish latency in sensory neurons and then reactivate to infect epithelial cells in the mucosa or skin, resulting in a vesicular rash. Licensed antivirals inhibit virus replication, but do not affect latency. On reactivation, VZV causes herpes zoster, also known as shingles. The 76-year-old first author of this paper published an autobiography of his own severe herpes zoster ophthalmicus (HZO) infection with orbital edema, which is considered an emergency condition. Acyclovir (ACV) treatment was complemented with an immunostimulatory viral therapy, which resolved most symptoms within a few days. The orally administered live-attenuated infectious bursal disease vaccine virus (IBDV) delivers its double-stranded RNA (dsRNA) cargo to host cells and activates the natural antiviral interferon (IFN) gene defense system from within the host cells. IBDV has already been demonstrated to be safe and effective against five different families of viruses, hepatitis A virus (HAV), hepatitis B and C virus (HBV/HCV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and varicella zoster virus (VZV). Here we propose a short phase I/II trial in elderly shingles patients who will be assigned to receive either ACV monotherapy or ACV combined with R903/78, an attenuated immunostimulatory IBDV strain. The primary endpoints will be safety, but the efficacy of the combination therapy against the ACV monotherapy also will be assessed.
ABSTRACT
Broiler population is one of the most important segments of livestock due to its significant contribution in white meat production. Infectious disease outbreaks adversely influence the production potential and consequently cause economic losses. Epidemiological data regarding magnitude of these disease outbreaks is of fundamental importance for planning of a comprehensive control strategy. With retrospective design, this study was conducted from January 2013 through December 2017 in order to assess the disease burden on broilers reared in different open type poultry houses. Out of total 658 commercial farms with capacity of 4221800 broilers, across Chakwal, a representative sample of 70 farms with capacity of 448000 broilers was randomly selected for collection and analysis of disease data. Five years' data of these randomly selected farms revealed highest (44.64%) crude morbidity during monsoon season followed by 23.92%, 22.12% and 17.49% for winter, spring and post-monsoon seasons respectively. The highest (14.90%) prevalence was recorded for new castle disease followed by infectious bursal disease (11.79%), pullorum disease (11.17%), colibacillosis (8.71%), infectious bronchitis (7.87%), inclusion body hepatitis (7.79%), chronic respiratory disease (7.67%), necrotic enteritis (6.48%), coccidiosis (6.09%), mycotoxicosis (5.43%), fowl cholera (4.74%), infectious coryza (4.41%), fowl typhoid (4.22%), omphalitis (3.71%) and hydropericardium syndrome (0.05%). Maximum share in crude morbidity was contributed by bacterial diseases with highest proportional morbidity of 48.68% followed by viral (40.32%), parasitic (5.80%) and fungal (5.20%) diseases. This epidemiological data represents true picture of study population and is a valuable tool for planning of prevention strategy and research priorities.
ABSTRACT
Exotic pest and disease investigations are managed and reported by the Ministry for Primary Industries' (MPI's) Diagnostic and Surveillance Directorate. This article presents a summary of investigations of suspect exotic and emerging pests and diseases in New Zealand during the period from July to September 2021.
ABSTRACT
Infectious bronchitis virus (IBV) causes an acute, highly contagious viral respiratory disease in poultry with huge economic impact and extremely difficult to control due to its multiple serotypes. The disease could be prevented by rapid diagnosis either molecular or serological test. However, the later test is inexpensive such as heamagglutination inhibition test (HI), but IBV fail to give Heamagglutination (HA) reaction without pretreatment. Therefore, we designed this study for preparation of IBV antigen by treating with different enzymes for HA reaction. IBV local isolates were characterized by SDS-PAGE and RT-PCR. The indigenous isolate HA antigens were treated with different proteolytic enzymes trypsin, neuraminidase and phospholipase C. The prepared antigen were stored at -86oC and used for HA test. All antigen prepared by different enzyme were found to give significant HA titer up to 7 log2 . During stability test antigen prepared by phospholipase C were found most stable up to six month by giving constant 7 log2 HA titer, while neuraminidase induced antigen were stable up to five months (7 log2). Trypsin treated antigen were readily lost its activity from 7 log2 to 2 log2 after two months of incubation. During specificity test all antigens showed specific effect on IBV by eliciting agglutination of RBCs while other avian viruses avian influenza (AI), new castle disease virus (NDV) and infectious bursal disease virus (IBDV) were not affected by enzymatic inductions. Therefore, the antigen prepared by phospholipase C has been found to be more effective for HI test for rapid diagnosis of IBV during infection.
ABSTRACT
More than 200 viruses infect humans but drugs are available for fewer than ten. To narrow the gap between 'bugs and drugs', a paradigm shift is required. The "one drug, one bug" approach should be supplemented by the "one drug, multiple bugs" strategy such that the host is targeted rather than the virus. The revolutionary viral superinfection therapy (SIT) activates the antiviral interferon gene natural defense system of host cells from within by an attenuated infectious bursal disease virus (IBDV) that releases its double-stranded RNA (dsRNA) cargo inside the cells. An attenuated IBDV vaccine strain has resolved hepatitis A virus infection (HAV) in marmoset monkeys and hepatitis B and C virus infections (HBV/HCV) in 42 patients with acute HBV or HCV. SIT was also safe and effective in four hepatically decompensated, chronically infected HBV and HCV patients. The proof-of-principle of SIT was demonstrated first in a 43-year-old male patient with COVID-19. Three doses of IBDV (3x106 IU) alleviated most of his COVID-19 symptoms, even the sense of smell returned within a week. Two additional COVID-19 patients responded similarly to oral treatment with IBDV. Furthermore, a severe herpes zoster ophthalmicus with orbital edema was healed within few days by combination of acyclovir and 7 doses IBDV (7x106 IU). IBDV is simple to manufacture and will be affordable even in resource limited settings. Acid resistant IBDV can be orally administered in an outpatient setting providing the greatest ease of dosing and the highest chance of patient compliance. Under an Emergency Use Authorization, the broad-based IBDV drug candidate could be tested immediately in clinical trials and rapidly distributed to millions of early-stage patients with COVID-19. The German Paul Ehrlich Institute supports such a phase I safety study for persons acutely infected with SARSCoV-2. An expert team of the US National Institutes of Health-sponsored ACTIV public-private partnership came to the conclusion that the IBDV drug candidate shows merit as a potential treatment for COVID-19 and an FDA approved clinical trial is in the pipelines in Los Angeles.